Go to
JCI Insight
Citations to this article
Nicholas R. Bertos, Morag Park
Published October 3, 2011
Citation Information: J Clin Invest. 2011;121(10):3789-3796. https://doi.org/10.1172/JCI57100.
Citation Information: J Clin Invest. 2011;121(10):3789-3796. https://doi.org/10.1172/JCI57100.
Abstract
Breast cancer, rather than constituting a monolithic entity, comprises heterogeneous tumors with different clinical characteristics, disease courses, and responses to specific treatments. Tumor-intrinsic features, including classical histological and immunopathological classifications as well as more recently described molecular subtypes, separate breast tumors into multiple groups. Tumor-extrinsic features, including microenvironmental configuration, also have prognostic significance and further expand the list of tumor-defining variables. A better understanding of the features underlying heterogeneity, as well as of the mechanisms and consequences of their interactions, is essential to improve targeting of existing therapies and to develop novel agents addressing specific combinations of features.
Authors
Nicholas R. Bertos, Morag Park
Total citations by year
Citation information
Citations to this article (106)
| Title and authors | Publication | Year |
|---|---|---|
|
The TGFβ2-Snail1-miRNA(TGFβ2) Circuitry is Critical for the Development of Aggressive Functions in Breast Cancer.
Luo L, Xu N, Fan W, Wu Y, Chen P, Li Z, He Z, Liu H, Lin Y, Zheng G |
Clinical and Translational Medicine | 2024 |
|
Educational level and characteristics of invasive breast cancer: findings from a French prospective cohort.
Berger E, Gelot A, Fournier A, Dossus L, Boutron-Ruault MC, Severi G, Castagné R, Delpierre C |
Cancer causes & control : CCC | 2024 |
|
Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges
Lehmann U |
Cancers | 2024 |
|
A retrospective cohort study to evaluate disease burden, health care resource utilization, and costs in patients with breast cancer in Dubai, UAE
Hamza D, Zayed M, Tahoun N, Farghaly M, Kumaresan S, Ramachandrachar B, Ali A |
BMC health services research | 2024 |
|
ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity
Zamora I, Gutiérrez M, Pascual A, Pajares MJ, Barajas M, Perez LM, You S, Knudsen BS, Freeman MR, Encío IJ, Rotinen M |
Cellular Oncology (Dordrecht, Netherlands) | 2024 |
|
Landscape of NcRNAs involved in drug resistance of breast cancer.
Kang Y |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023 |
|
moBRCA-net: a breast cancer subtype classification framework based on multi-omics attention neural networks
Choi JM, Chae H |
BMC bioinformatics | 2023 |
|
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
Xu B, Zhang Q, Hu X, Li Q, Sun T, Li W, Ouyang Q, Wang J, Tong Z, Yan M, Li H, Zeng X, Shan C, Wang X, Yan X, Zhang J, Zhang Y, Wang J, Zhang L, Lin Y, Feng J, Chen Q, Huang J, Zhang L, Yang L, Tian Y, Shang H |
Acta pharmaceutica Sinica. B | 2023 |
|
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, Morellato A, Ala U, Taverna D, Turco E, Defilippi P |
Frontiers in Oncology | 2023 |
|
Using immunohistochemistry to classify the molecular subtypes of Paget's disease of the breast
Cai Y, Cheng Z, Nangong J, Zheng X, Yuan Z |
Cancer Medicine | 2023 |
|
The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer
Ye P, Feng L, Shi S, Dong C |
Cancers | 2022 |
|
5’isomiR-183-5p|+2 elicits tumor suppressor activity in a negative feedback loop with E2F1
Li X, Michels BE, Tosun OE, Jung J, Kappes J, Ibing S, Nataraj NB, Sahay S, Schneider M, Wörner A, Becki C, Ishaque N, Feuerbach L, Heßling B, Helm D, Will R, Yarden Y, Müller-Decker K, Wiemann S, Körner C |
Journal of experimental & clinical cancer research : CR | 2022 |
|
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J |
Breast Cancer Research and Treatment | 2022 |
|
Who's Who? Discrimination of Human Breast Cancer Cell Lines by Raman and FTIR Microspectroscopy.
Santos IP, Martins CB, Batista de Carvalho LAE, Marques MPM, Batista de Carvalho ALM |
Cancers | 2022 |
|
The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature
Lisencu LA, Trancă S, Bonci EA, Pașca A, Mihu C, Irimie A, Tudoran O, Balacescu O, Lisencu IC |
Biomedicines | 2022 |
|
Socioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women
de Almeida LM, Cortés S, Vilensky M, Valenzuela O, Cortes-Sanabria L, de Souza M, Barbeito RA, Abdelhay E, Artagaveytia N, Daneri-Navarro A, Llera AS, Müller B, Podhajcer OL, Velazquez C, Alcoba E, Alonso I, Bravo AI, Camejo N, Carraro DM, Castro M, Cataldi S, Cayota A, Cerda M, Colombo A, Crocamo S, Del Toro-Arreola A, Delgadillo-Cristerna R, Delgado L, Breitenbach MD, Fernández E, Fernández J, Fernández W, Franco-Topete RA, Gaete F, Gómez J, Gonzalez-Ramirez LP, Guerrero M, Gutierrez-Rubio SA, Jalfin B, Lopez-Vazquez A, Loria D, Míguez S, Moran-Mendoza AD, Morgan-Villela G, Mussetti C, Nagai MA, Oceguera-Villanueva A, Reis RM, Retamales J, Rodriguez R, Rosales C, Salas-Gonzalez E, Segovia L, Sendoya JM, Silva-Garcia AA, Viña S, Zagame L, Jones B, Szklo M |
Frontiers in Oncology | 2022 |
|
Hypoxia-inducible CircPFKFB4 Promotes Breast Cancer Progression by Facilitating the CRL4DDB2 E3 Ubiquitin Ligase-mediated p27 Degradation
Chen H, Yang R, Xing L, Wang B, Liu D, Ou X, Deng Y, Jiang R, Chen J |
International journal of biological sciences | 2022 |
|
Thermomagnetic Resonance Effect of the Extremely Low Frequency Electromagnetic Field on Three-Dimensional Cancer Models
Bergandi L, Lucia U, Grisolia G, Salaroglio IC, Gesmundo I, Granata R, Borchiellini R, Ponzetto A, Silvagno F |
International journal of molecular sciences | 2022 |
|
«Salivaomics» of Different Molecular Biological Subtypes of Breast Cancer
Bel\u2019skaya LV, Sarf EA |
Current issues in molecular biology | 2022 |
|
The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review.
Asgari-Karchekani S, Aryannejad A, Mousavi SA, Shahsavarhaghighi S, Tavangar SM |
Medical Oncology | 2022 |
|
Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes
Fina E |
Cancers | 2022 |
|
Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies
N Zhao, J Rosen |
Seminars in Cancer Biology | 2021 |
|
Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia
K Al-Saleh, T Salah, M Arafah, S Husain, A Al-Rikabi, NA El-Aziz, E Tagliabue |
PloS one | 2021 |
|
Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer
MM Moubarak, N Chanouha, NA Ibrahim, H Khalife, H Gali-Muhtasib |
World journal of clinical oncology | 2021 |
|
Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients
Lu Y, Tong Y, Chen X, Shen K |
Frontiers in Oncology | 2021 |
|
Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells
S Fiorentino, C Urueña, P Lasso, K Prieto, A Barreto |
Frontiers in Oncology | 2020 |
|
Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy.
Vignoli A, Muraro E, Miolo G, Tenori L, Turano P, Di Gregorio E, Steffan A, Luchinat C, Corona G |
Cancers | 2020 |
|
IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways
I Gyurján, S Rosskopf, JA Coronell, D Muhr, C Singer, A Weinhäusel |
Oncotarget | 2019 |
|
The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models
Cleris, Daidone, Fina, Cappelletti |
Cells | 2019 |
|
Stratification of Breast Cancer by Integrating Gene Expression Data and Clinical Variables
Z He, J Zhang, X Yuan, , Z Liu, Y Zhang |
Molecules (Basel, Switzerland) | 2019 |
|
Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India
A Gogia, SV Deo, D Sharma, RK Phulia, S Thulkar, PS Malik, S Mathur |
Journal of Global Oncology | 2019 |
|
Promyelocytic leukemia protein ( PML ) controls breast cancer cell proliferation by modulating Forkhead transcription factors
N Sachini, P Arampatzi, A Klonizakis, C Nikolaou, T Makatounakis, EW Lam, A Kretsovali, J Papamatheakis |
Molecular Oncology | 2019 |
|
Image-based Classification of Tumor Type and Growth Rate using Machine Learning: a preclinical study
TT Tang, JA Zawaski, KN Francis, AA Qutub, MW Gaber |
Scientific Reports | 2019 |
|
In Vitro and In Vivo Study on the Effect of Lysosome-associated Protein Transmembrane 4 Beta on the Progression of Breast Cancer
D Tao, J Liang, Y Pan, Y Zhou, Y Feng, L Zhang, J Xu, H Wang, P He, J Yao, Y Zhao, Q Ning, W Wang, W Jiang, J Zheng, X Wu |
Journal of Breast Cancer | 2019 |
|
Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer
J Li, Y Mo, B He, Q Gao, C Luo, C Peng, W Zhao, Y Ma, Y Yang |
British Journal of Radiology | 2019 |
|
Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.
Zhao Y, Wang X, Huang Y, Zhou X, Zhang D |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2019 |
|
Breast cancer stem cells and the challenges of eradication: a review of novel therapies
F Saeg, M Anbalagan |
Stem Cell Investigation | 2018 |
|
Stromal PTEN determines mammary epithelial response to radiotherapy
GM Sizemore, S Balakrishnan, KA Thies, AM Hammer, ST Sizemore, AJ Trimboli, MC Cuitiño, SA Steck, G Tozbikian, RD Kladney, N Shinde, M Das, D Park, S Majumder, S Krishnan, L Yu, SA Fernandez, A Chakravarti, PG Shields, JR White, LD Yee, TJ Rosol, T Ludwig, M Park, G Leone, MC Ostrowski |
Nature Communications | 2018 |
|
Breast cancer identification via modeling of peripherally circulating miRNAs
X Cui, Z Li, Y Zhao, A Song, Y Shi, X Hai, W Zhu |
PeerJ | 2018 |
|
Breast Cancer Heterogeneity: A focus on Epigenetics and In Vitro 3D Model Systems
Palamadai Krishnan Suresh |
Cell Journal (Yakhteh) | 2018 |
|
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
J Liu, Z Duan, W Guo, L Zeng, Y Wu, Y Chen, F Tai, Y Wang, Y Lin, Q Zhang, Y He, J Deng, RL Stewart, C Wang, PC Lin, S Ghaffari, BM Evers, S Liu, MM Zhou, BP Zhou, J Shi |
Nature Communications | 2018 |
|
Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration
IY Hachim, M Villatoro, L Canaff, MY Hachim, J Boudreault, H Haiub, S Ali, JJ Lebrun |
Scientific Reports | 2017 |
|
Tumor Microenvironment Heterogeneity: Challenges and Opportunities
F Runa, S Hamalian, K Meade, P Shisgal, PC Gray, JA Kelber |
Current Molecular Biology Reports | 2017 |
|
Stromal PDGFR-α Activation Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and Accelerates Tumor Growth
AM Hammer, GM Sizemore, VC Shukla, A Avendano, ST Sizemore, JJ Chang, RD Kladney, MC Cuitiño, KA Thies, Q Verfurth, A Chakravarti, LD Yee, G Leone, JW Song, SN Ghadiali, MC Ostrowski |
Neoplasia (New York, N.Y.) | 2017 |
|
Identification of novel dysregulated key genes in Breast cancer through high throughput ChIP-Seq data analysis
U Raj, I Aier, R Semwal, PK Varadwaj |
Scientific Reports | 2017 |
|
Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
Z Feng, H Wen, X Ju, R Bi, X Chen, W Yang, X Wu |
Oncotarget | 2017 |
|
Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease
A Mehrgou, M Akouchekian |
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences | 2017 |
|
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis
L Nogués, C Reglero, V Rivas, A Salcedo, V Lafarga, M Neves, P Ramos, M Mendiola, A Berjón, K Stamatakis, XZ Zhou, KP Lu, D Hardisson, F Mayor, P Penela |
EBioMedicine | 2016 |
|
Cell Fate Decisions During Breast Cancer Development
K Gross, A Wronski, A Skibinski, S Phillips, C Kuperwasser |
Journal of Developmental Biology | 2016 |
|
Oestrogen receptor negativity in breast cancer: a cause or consequence?
VN Gajulapalli, VL Malisetty, SK Chitta, B Manavathi |
Bioscience Reports | 2016 |
|
Proteogenomics connects somatic mutations to signalling in breast cancer
P Mertins, DR Mani, KV Ruggles, MA Gillette, KR Clauser, P Wang, X Wang, JW Qiao, S Cao, F Petralia, E Kawaler, F Mundt, K Krug, Z Tu, JT Lei, ML Gatza, M Wilkerson, CM Perou, V Yellapantula, K Huang, C Lin, MD McLellan, P Yan, SR Davies, RR Townsend, SJ Skates, J Wang, B Zhang, CR Kinsinger, M Mesri, H Rodriguez, L Ding, AG Paulovich, D Fenyö, MJ Ellis, SA Carr |
Nature | 2016 |
|
The tumor microenvironment in esophageal cancer
EW Lin, TA Karakasheva, PD Hicks, AJ Bass, AK Rustgi |
Oncogene | 2016 |
|
Associations of the Transforming Growth Factor β/Smad Pathway, Body Mass Index, and Physical Activity With Breast Cancer Outcomes: Results From the Shanghai Breast Cancer Study
Y Su, H Cai, Y Zheng, Q Qiu, W Lu, XO Shu, Q Cai |
American Journal of Epidemiology | 2016 |
|
Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools
N Akrap, D Andersson, E Bom, P Gregersson, A Ståhlberg, G Landberg |
Stem Cell Reports | 2016 |
|
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
S Kurozumi, M Padilla, M Kurosumi, H Matsumoto, K Inoue, J Horiguchi, I Takeyoshi, T Oyama, J Ranger-Moore, DC Allred, E Dennis, H Nitta |
Breast Cancer Research and Treatment | 2016 |
|
Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups
D Netanely, A Avraham, A Ben-Baruch, E Evron, R Shamir |
Breast Cancer Research | 2016 |
|
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells
F Roggiani, D Mezzanzanica, K Rea, A Tomassetti |
International journal of molecular sciences | 2016 |
|
Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
T Vanderah, K Hanlon, A Lozano-Ondoua, P Umaretiya, A Symons-Ligouri, A Chandramouli, J Moy, W Kwass, P Mantyh, M Nelson |
Breast cancer : targets and therapy | 2016 |
|
Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia
H Miao, M Hartman, HM Verkooijen, NA Taib, HS Wong, S Subramaniam, CH Yip, EY Tan, P Chan, SC Lee, N Bhoo-Pathy |
BMC Cancer | 2016 |
|
Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies
FL Nobrega, D Ferreira, IM Martins, M Suarez-Diez, J Azeredo, LD Kluskens, LR Rodrigues |
BMC Cancer | 2016 |
|
Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer
R Kumavath, M Azad, P Devarapalli, S Tiwari, S Kar, D Barh, V Azevedo, AP Kumar |
Bioinformation | 2016 |
|
Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR − /HER2 + breast cancers
R Rodriguez-Barrueco, J Yu, LP Saucedo-Cuevas, M Olivan, D Llobet-Navas, P Putcha, V Castro, EM Murga-Penas, A Collazo-Lorduy, M Castillo-Martin, M Alvarez, C Cordon-Cardo, K Kalinsky, M Maurer, A Califano, JM Silva |
Genes & development | 2015 |
|
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis
K Spring, P Fournier, L Lapointe, C Chabot, J Roussy, S Pommey, J Stagg, I Royal |
Oncogene | 2015 |
|
Triple Negative Breast Cancer: Nanosolutions for a Big Challenge
TF Mendes, LD Kluskens, LR Rodrigues |
Advanced Science | 2015 |
|
The Changing World of Breast Cancer: A Radiologistʼs Perspective
CK Kuhl |
Investigative Radiology | 2015 |
|
Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer
Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H |
Oncotarget | 2015 |
|
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study
Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH |
Oncotarget | 2015 |
|
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen ¿ urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression
A Csiszar, B Kutay, S Wirth, U Schmidt, S Macho-Maschler, M Schreiber, M Alacakaptan, GF Vogel, K Aumayr, LA Huber, H Beug |
Breast Cancer Research | 2014 |
|
Regulation of mammary epithelial cell homeostasis by lncRNAs
AN Shore, JM Rosen |
The International Journal of Biochemistry & Cell Biology | 2014 |
|
Changing genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype/phenotype relationships
B Gottlieb, LK Beitel, M Trifiro |
Human genomics | 2014 |
|
PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells
Y Shi, F Zhou, F Jiang, H Lu, J Wang, C Cheng |
Chinese Journal of Cancer Research | 2014 |
|
Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population
E Leung, JE Kim, M Askarian-Amiri, GJ Finlay, BC Baguley |
BioMed Research International | 2014 |
|
Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression
EV Denisov, NV Litviakov, MV Zavyalova, VM Perelmuter, SV Vtorushin, MM Tsyganov, TS Gerashchenko, EY Garbukov, EM Slonimskaya, NV Cherdyntseva |
Scientific Reports | 2014 |
|
Illuminating breast cancer invasion: diverse roles for cell–cell interactions
KJ Cheung, AJ Ewald |
Current Opinion in Cell Biology | 2014 |
|
Chromosome-breakage genomic instability and chromothripsis in breast cancer
E Przybytkowski, E Lenkiewicz, MT Barrett, K Klein, S Nabavi, CM Greenwood, M Basik |
BMC Genomics | 2014 |
|
Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration
J Pignatelli, S Goswami, JG Jones, TE Rohan, E Pieri, X Chen, E Adler, D Cox, S Maleki, A Bresnick, FB Gertler, JS Condeelis, MH Oktay |
Science signaling | 2014 |
|
Prognostic implications of receptor discordance between primary and recurrent breast cancer
A Matsumoto, H Jinno, T Murata, T Seki, M Takahashi, T Hayashida, K Kameyama, Y Kitagawa |
International Journal of Clinical Oncology | 2014 |
|
FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis.
Huang O, Jiang M, Zhang X, Chen X, Wu J, Shen K |
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine | 2014 |
|
Diffusion magnetic resonance imaging in breast cancer characterisation: correlations between the apparent diffusion coefficient and major prognostic factors.
Belli P, Costantini M, Bufi E, Giardina GG, Rinaldi P, Franceschini G, Bonomo L |
La radiologia medica | 2014 |
|
Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells
A Papi, G Storci, T Guarnieri, SD Carolis, S Bertoni, N Avenia, A Sanguinetti, A Sidoni, D Santini, C Ceccarelli, M Taffurelli, M Orlandi, M Bonafé |
PloS one | 2013 |
|
In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness
F Brugnoli, S Grassilli, M Piazzi, M Palomba, E Nika, A Bavelloni, S Capitani, V Bertagnolo |
Molecular Cancer | 2013 |
|
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence"
M Tarabichi, A Antoniou, M Saiselet, JM Pita, G Andry, JE Dumont, V Detours, C Maenhaut |
Cancer metastasis reviews | 2013 |
|
Phenotypic Drift as a Cause for Intratumoral Morphological Heterogeneity of Invasive Ductal Breast Carcinoma Not Otherwise Specified
MV Zavyalova, EV Denisov, LA Tashireva, TS Gerashchenko, NV Litviakov, NA Skryabin, SV Vtorushin, NS Telegina, EM Slonimskaya, NV Cherdyntseva, VM Perelmuter |
BioResearch Open Access | 2013 |
|
STAT signaling in different breast cancer sub-types
PA Furth |
Molecular and Cellular Endocrinology | 2013 |
|
Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer
Q Peng, L Zhao, Y Hou, Y Sun, L Wang, H Luo, H Peng, M Liu |
PloS one | 2013 |
|
Repression of Zeb1 and Hypoxia Cause Sequential Mesenchymal-to-Epithelial Transition and Induction of Aid, Oct4, and Dnmt1, Leading to Immortalization and Multipotential Reprogramming of Fibroblasts in Spheres
Y Liu, P Mukhopadhyay, MM Pisano, X Lu, L Huang, Q Lu, DC Dean |
Stem Cells | 2013 |
|
No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women
T Dorjgochoo, Y Zheng, YT Gao, X Ma, J Long, P Bao, B Zhang, W Wen, W Lu, W Zheng, XO Shu, A Beeghly-Fadiel |
Cancer Epidemiology | 2013 |
|
Wnt signaling in triple negative breast cancer is associated with metastasis
N Dey, BG Barwick, CS Moreno, M Ordanic-Kodani, Z Chen, G Oprea-Ilies, W Tang, C Catzavelos, KF Kerstann, GW Sledge, M Abramovitz, M Bouzyk, P De, BR Leyland-Jones |
BMC Cancer | 2013 |
|
XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients
Y Zhou, W Zhou, Q Liu, Z Fan, Z Yang, Q Tu, L Li, H Liu |
Tumor Biology | 2013 |
|
The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness
D Sisci, P Maris, MG Cesario, W Anselmo, R Coroniti, GE Trombino, F Romeo, A Ferraro, M Lanzino, S Aquila, M Maggiolini, L Mauro, C Morelli, S Andò |
Cell cycle (Georgetown, Tex.) | 2013 |
|
Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence
J Assi, G Srivastava, A Matta, MC Chang, PG Walfish, R Ralhan |
PloS one | 2013 |
|
Mass spectrometry imaging for in situ kinetic histochemistry
KB Louie, BP Bowen, S McAlhany, Y Huang, JC Price, J Mao, M Hellerstein, TR Northen |
Scientific Reports | 2013 |
|
Collective migration of cancer-associated fibroblasts is enhanced by overexpression of tight junction-associated proteins claudin-11 and occludin
GS Karagiannis, DF Schaeffer, CK Cho, N Musrap, P Saraon, I Batruch, A Grin, B Mitrovic, R Kirsch, RH Riddell, EP Diamandis |
Molecular Oncology | 2013 |
|
Characterising the tumour morphological response to therapeutic intervention: an ex vivo model
A Savage, E Katz, A Eberst, RE Falconer, A Houston, DJ Harrison, J Bown |
Disease models & mechanisms | 2013 |
|
Association between vitamin D receptor poly(A) polymorphism and breast cancer risk: a meta-analysis.
Xu J, Li H, Gu L, Zhou X |
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine | 2013 |
|
Multiscale Models of Breast Cancer Progression
A Chakrabarti, S Verbridge, AD Stroock, C Fischbach, JD Varner |
Annals of Biomedical Engineering | 2012 |
|
Intra-tumour heterogeneity: a looking glass for cancer?
A Marusyk, V Almendro, K Polyak |
Nature Reviews Cancer | 2012 |
|
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy: Figure 1
MA Swartz, N Iida, EW Roberts, S Sangaletti, MH Wong, FE Yull, LM Coussens, YA DeClerck |
Cancer research | 2012 |
|
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells
J Węsierska-Gądek, N Zulehner, F Ferk, A Składanowski, O Komina, M Maurer |
Biochemical Pharmacology | 2012 |
|
Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells
JW Ruan, YC Liao, I Lua, MH Li, CY Hsu, JH Chen |
Breast Cancer Research | 2012 |
|
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients
M Svoboda, J Sana, M Redova, J Navratil, M Palacova, P Fabian, O Slaby, R Vyzula |
Diagnostic Pathology | 2012 |
|
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases
JC Hall, L Casciola-Rosen, AE Berger, EK Kapsogeorgou, C Cheadle, AG Tzioufas, AN Baer, A Rosen |
Proceedings of the National Academy of Sciences | 2012 |
|
Py2T murine breast cancer cells, a versatile model of TGFβ-induced EMT in vitro and in vivo
L Waldmeier, N Meyer-Schaller, M Diepenbruck, G Christofori |
PloS one | 2012 |
|
Heterogeneity in breast cancer
Kornelia Polyak |
Journal of Clinical Investigation | 2011 |
|
MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b
G Roscigno, C Quintavalle, E Donnarumma, I Puoti, A Diaz-Lagares, M Iaboni, D Fiore, V Russo, M Todaro, G Romano, R Thomas, G Cortino, M Gaggianesi, M Esteller, CM Croce, G Condorelli |
Oncotarget | 2010 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)